Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.


TSX:CPH - Post by User

Bullboard Posts
Comment by Stylesson Oct 01, 2015 12:15pm
60 Views
Post# 24153626

RE:RE:RE:RE:RE:Caution

RE:RE:RE:RE:RE:CautionI disagree with many of your points.

1 - Nobody shorted this stock in any meaningful size. there was never enough float to short the stock. Please go have a look at the short  interest history. It peaked at 1.5% of shares oustanding. Nothing. This stock fell on a lack of execution and poor management. That's it.

2- This is a huge tax loss canadidate for anyone who's holding it given it's down 70% this year. Tax loss selling typically starts in November and goes to mid December. I can see thsi continuing to drop if markets stay flat to negative. 

3- If you believe in seasonality, why play a beaten up no liquidity / no institutional name like CPH. If you believe markets will rally, do you think CPH will really get any love? This thing is mainly insiders and retail. If you anticipate a Q4 rally, you're much better off being long VRX and CXR. With Tier 1 quality names on fire sale prices, why would you buy CPH? CPH is Tier III or IV at best in terms of quality. Names like CXR are cheaper / comparable in valuation to CPH.

4 - Technicals suggest there could be something here, but there's no fundamental reason to own the stock.

This is a dud. Management got what they deserved. They own 10M shares of this P-O-S. Lieseeker talks about fraud, but reality is there's no one who lost more than management and board here.
Bullboard Posts